Close menu




October 26th, 2021 | 13:56 CEST

Nel, BYD, BrainChip: This looks good

  • Technology
Photo credits: brainchipinc.com

While shares from the technology sector have been very volatile in recent weeks, the knot has burst at BYD, and the share has risen to a new record high. Rumors about Tesla and Apple have contributed to this. Both are said to be in talks with the Chinese specialist around electric mobility. The shares of Nel and BrainChip have also developed very positively recently. Both have invested heavily and could now reap the rewards of these investments. All three shares have further room for improvement. You can read why here.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: NEL ASA NK-_20 | NO0010081235 , BYD CO. LTD H YC 1 | CNE100000296 , BRAINCHIP HOLDINGS LTD | AU000000BRN8

Table of contents:


    BrainChip on the verge of a breakthrough?

    BrainChip provided an exclamation mark in recent days. The share of the Australian chip developer with a price jump from EUR 0.25 to EUR 0.30. This could be the starting signal for a year-end rally, then Pitt Street Research still sees significant upside potential compared to the peer group and recommends the Brainchip share with a price target of EUR 0.94 to buy. There are also operational reasons for this.

    First, Ken Scarince, CFO of the artificial intelligence (AI) specialist, had expressed optimism at the International Investment Forum (IFF): "We orient ourselves and our chips to the human brain and thus offer the most efficient AI solution ever produced." The Akida chip functions completely autonomously and is not dependent on other components. That is another reason why the chip requires only half the energy compared to its competitors, he said. The innovation developed by BrainChip works based on impulses and events, and functions completely autonomously, processing so-called spikes instead of traditional computer data. In the process, Akida learns independently using artificial intelligence; the work is done directly on the chip and not in the data center. The management team sees areas of application in autonomous driving, IoT devices, robotics, medical diagnostics and security technology.

    Then last week came the long-awaited news: The developer kits can now be ordered from BrainChip. These include the X86 Shuttle PC development kit and an ARM-based Raspberry Pi development kit. Both kits use the AKD1000 chip on a mini PCI board. BrainChip's offering allows customers to begin internal testing and evaluation of Akida's "high-performance and ultra-low-power AI chip." If the two products deliver what BrainChip promises to customers, larger orders should only be a matter of time, and with them, reaching the Pitt Street price target. It would be a new all-time high.

    BYD: Tesla and Apple interested?

    The BYD share has already reached a new all-time high in the past week. This time, it was not sales figures in the automotive sector or orders for electrified commercial vehicles that caused investors to be in a buying mood, but rumors regarding the battery division. Accordingly, two US tech giants are interested in the cells of the Chinese. Initially, Chinese media had reported that Tesla also wanted to use blade batteries from BYD with LFP cells from the second quarter of 2022. An initial order with a volume of 10 GWh is said to have already been placed. The blade batteries are intended for the standard range variants of the Chinese-built Model 3 and Model Y. While there is no confirmation, Tesla announced that it would switch its standard range models to LFP batteries. And the BYD batteries have attracted Apple's interest as well. Various media have reported that BYD has entered the circle of possible battery suppliers for the iCar. However, talks are currently said to be on hold due to capacity bottlenecks in the development area. BYD's battery division has so far received little attention from investors, but this seems to be changing.

    Nel: Will hydrogen soon be competitive?

    Nel certainly cannot complain about too little attention. Recently, the positive comments on the hydrogen specialist have increased again. The Nel share gained more than 10% last week. Most recently, Nel reported that the expansion of the Heroya plant is on schedule. More than 500 megawatts are to be produced there automatically in the future. In addition, growth to 2 gigawatts is possible. Deliveries to customers Everfuel and Nikola are scheduled to start before the end of the fourth quarter. With the expansion and automation of the plant, Nel intends to exploit economies of scale and produce hydrogen at less than USD 1.50 per Kg. According to Nel, this would make hydrogen competitive with fossil fuels.


    Even in volatile times, individual stocks develop positively. In the case of BrainChip, investors speculate that the delivery of the test kits is the beginning of the breakthrough. Nel may have taken an important step toward hydrogen competitiveness with the plant expansion. If there is any truth in the rumors about deliveries to Tesla and Apple, the BYD share should still have significant room for improvement.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Armin Schulz on October 4th, 2022 | 10:58 CEST

    JinkoSolar, TubeSolar, Encavis - Shares for the energy turnaround

    • agritech
    • renewableenergies
    • Technology

    The phase-out of fossil energy generation is a done deal in Germany, but there is still a long way to go. Germany's share of renewable energies in electricity generation was 42.4% in 2021. However, this covered only 19.7% of Germany's energy consumption. Since the flare-up of the Ukraine crisis, the expansion of renewable energies is to be accelerated. A balanced mix is essential. Spring and summer are the main times for solar power, while in fall and winter, when the days are shorter, wind power is the primary source of electricity. If we want to achieve the 2030 targets, a massive expansion is essential. Today we take a look at three renewable energy companies.

    Read

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read